GlassScriptPhysician profile
Michael Martorana
NPI 1124460837
$4,745.16
in general payments reported to CMS, 2019-2025
20 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,323 · 2020: $329 · 2021: $386 · 2022: $441 · 2023: $675 · 2024: $205 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,951.96 | 2019-2021 | |
| Alcon Vision LLC | $818.61 | 2020-2025 | Precision 1, Dailies Total1, Dailies Aqua Comfort Plus |
| Johnson & Johnson Vision Care, INC. | $530.40 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $405.79 | 2022-2025 | Infuse |
| Shire North American Group INC | $160.00 | 2019 | |
| Abb Con-Cise Optical Group LLC | $120.97 | 2020-2025 | Contact Lens, Spectacle Lenses |
| Aerie Pharmaceuticals, INC. | $116.99 | 2019 | |
| Kala Pharmaceuticals, INC. | $115.83 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $102.95 | 2019 | |
| Abbvie INC. | $95.83 | 2023 | |
| Oyster Point Pharma, INC. | $64.19 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $53.01 | 2021-2025 | Cequa |
| Optos, INC. | $48.48 | 2022 | |
| Coopervision INC. | $40.04 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $27.52 | 2024 | Xdemvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23.23 | 2022 | |
| Synergeyes, INC. | $19.85 | 2021 | |
| Carl Zeiss Meditec Ag | $17.20 | 2020 | |
| Biotissue Holdings INC. | $16.56 | 2019 | |
| Sight Sciences, INC. | $15.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Martorana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.